Advanced hepatocellular carcinoma. Review of targeted molecular drugs
Journal Title: Annals of Hepatology - Year 2011, Vol 10, Issue 1
Abstract
Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world in terms of incidence, accounting for approximately 630 thousand new cases per year; in addition, HCC is the third most common cause of cancer death. Worldwide, the greatest risk factors for HCC are the infections caused by hepatitis B and C viruses, which increase the risk of developing the disease by about 20 times. The standard treatment in the early stages of the disease, such as surgical resection, local ablation and liver transplantation, are able to cure a proportion of patients, but most cases of HCC present in advanced stages, precluding the use of such treatments with curative intent. In these advanced stages, systemic treatments are commonly used. Unfortunately, chemotherapy with conventional cytotoxic agents is ineffective and does not seem to modify the natural history of disease. Treatment options for patients with advanced HCC are extremely limited, but the identification of signaling pathways, and the recognition of the role of these pathways in the pathogenesis of the disease resulted in the development of drugs directed at specific therapeutic targets. One such drug is Sorafenib, a kinase inhibitor with antiangiogenic and antiproliferative properties. In conclusion, Sorafenib has demonstrated survival benefits in patients with advanced HCC, thus representing a new standard reference for systemic treatment in these cases.
Authors and Affiliations
Rogério Alves, Daniele Alves, Betty Guz, Carla Matos, Monica Viana, Michele Harriz, Deborah Terrabuio, Mario Kondo, Otavio Gampel, Paula Polletti
Keywords
Related Articles
- EP ID EP77999
- DOI -
- Views 140
- Downloads 0
Treatment of polycystic liver disease: a hypothesis, patient characteristics, short and long-term results
Background. Non-total liver resecting invasive treatment of polycystic liver disease has different recurrence rates. The aim of this study is to illustrate why the recurrence rates are different. We established a hypothe...
Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma
Introduction. Considering the high prevalence of liver tumors and the impact on patient survival, a greater understanding of the biological behavior of those tumors if of great importance. The multidrug resistance gene (...
Recurrent giant cell hepatitis in an 18 year old liver transplant patient
The prevalence of nonalcoholic fatty liver disease in the Americas
Nonalcoholic fatty liver disease (NAFLD) is an alarming public health problem. The disease is one of the main causes of chronic liver disease worldwide and is directly linked to the increased prevalence of obesity and ty...
Novel cytochrome P450-2D6 promoter sequence variations in hepatitis C positive and negative subjects
Introduction. CYP2D6 is a liver enzyme that metabolizes more that 25% of drugs and thus may play a pivotal role in drug-drug interactions. The promoter sequences of cytochrome P450 2D6 (CYP2D6) gene could impact metaboli...